Ally Bridge Group operates as a life science-dedicated specialist and active investor in surgical robotics.
Portfolio
1
companies
Charles Chon
Partner and Head of MedTech
The upsized funding round was led by existing backers including Ally Bridge Group and Lightrock.
"Versius is very well suited to our needs as a world-leading thoracic surgery department. We have successfully helped patients get the benefit of robotic assisted surgery and we look forward to developing our robotics programme working with CMR and other centres around the world as the adoption of Versius continues."
The funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group to support international expansion and technological development.
"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."
.png)